ERBB3 EXPRESSION ASSESSED BY IMMUNOHISTOCHEMISTRY (IHC) IN NON-SMALL CELL LUNG CANCER (NSCLC) TUMORS WITH EGFR MUTATION, BEFORE EGFR-TYROSINE-KINASE INHIBITOR (EGFR-TKI) EXPOSURE

被引：0

作者：

Felip, Enriqueta ^{[1
]}

Hernandez-Losa, Javier ^{[2
]}

Murtra-Garrell, Nuria ^{[1
]}

Freixinos, Victor ^{[1
]}

Salcedo, Maite ^{[2
]}

Tallada, Natalia ^{[2
]}

Teixido, Cristina ^{[2
]}

Martinez, Pablo ^{[1
]}

Cedres, Susana ^{[1
]}

Lopez, Eva ^{[3
]}

Pandielle, Anastasio

Cajal, Santiago Ramon Y. ^{[2
]}

机构：

[1] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain

[2] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain

[3] Vall Hebron Hosp, Dept Stat, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期

关键词：

EGFR mutation; ErbB3;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S1104 / S1105

页数：2

共 50 条

[31] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
Guo-Hao Xia
Yun Zeng
Ying Fang
Shao-Rong Yu
Li Wang
Mei-Qi Shi
Wei-Li Sun
Xin-En Huang
Jia Chen
Ji- Feng Feng
Cancer Biology & Medicine, 2014, 11 (04) : 270 - 276
[32] The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
Chen, Dougfang
Chu, Tianqing
Chang, Qing
Zhang, Yanwei
Xiong, Liwen
Qiao, Rong
Teng, Jiajun
Han, Baohui
Zhong, Runbo
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (09)
[33] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
Mathy, A.
Nederlof, P.
Boerrigter, L.
Van 't Veer, L.
De Jong, D.
Baas, P.
Burgers, S.
Van Zandwijk, N.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
[34] Analysis of the EGFR mutations in non-small cell lung cancer patients after EGFR-TKI treatment.
Yamaguchi, H.
Ikeda, T.
Tomonaga, N.
Nakano, H.
Kitazaki, T.
Doi, S.
Nakatomi, K.
Iida, T.
Nakamura, Y.
Kohno, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[35] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
Xu, Jianlin
Jin, Bo
Chu, Tianqing
Dong, Xue
Yang, Haitang
Zhang, Yanwei
Wu, Dan
Lou, Yuqing
Zhang, Xueyan
Wang, Huiming
Han, Baohui
LUNG CANCER, 2016, 96 : 87 - 92
[36] Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
Tan, Aaron C.
Teh, Yi Lin
Lai, Gillianne G. Y.
Tan, Daniel S. W.
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 431 - 435
[37] Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report
Wang, Zhiyi
Zhou, Pu
Li, Guanghui
ONCOLOGY LETTERS, 2016, 12 (01) : 356 - 360
[38] EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
Tsai, Jeng-Shiuan
Su, Po-Lan
Yang, Szu-Chun
Chang, Chao-Chun
Lin, Chia-Ying
Yen, Yi-Ting
Tseng, Yau-Lin
Lai, Wu-Wei
Lin, Chien-Chung
Su, Wu-Chou
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (09) : 1729 - 1739
[39] Negative impact of ratio of the microvascular area to tumor area on the response to EGFR-TKI in non-small cell lung cancer with an EGFR mutation
Anai, Moriyasu
Saruwatari, Koichi
Imamura, Kosuke
Fujino, Kosuke
Jodai, Takayuki
Sakata, Shinya
Iyama, Shinji
Tomita, Yusuke
Saeki, Sho
Ichiyasu, Hidenori
Ikeda, Koei
Suzuki, Makoto
Sakagami, Takuro
JOURNAL OF THORACIC DISEASE, 2024, 16 (02) : 1151 - 1160
[40] EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment
Que, Dan
Xiao, He
Zhao, Baojian
Zhang, Xu
Wang, Qiushi
Xiao, Hualiang
Wang, Ge
CANCER BIOLOGY & THERAPY, 2016, 17 (03) : 320 - 327

← 1 2 3 4 5 →